JLL vs PMCB · P/E 23, rev $23.43B vs $8.6M cap
Jones Lang LaSalle Incorporated (JLL) versus PharmaCyte Biotech Inc (PMCB) — a side-by-side from cached financials, not a winner call.
Jones Lang LaSalle Incorporated (JLL) is a real estate services company listed on US.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
Latest reported JLL revenue for 2024-12-31 was $23.43B. Net income was $546.8M. Revenue was up 12.9% from 2023-12-31 to 2024-12-31. JLL currently screens at market cap $12.12B and trailing P/E 23.0.
Latest reported PMCB revenue for 2025-04-30 was $0. Net income was $30.7M. PMCB currently screens at market cap $8.6M.
JLL currently screens at market cap $12.12B and trailing P/E 23.0. PMCB currently screens at market cap $8.6M.
Not investment advice. Open the JLL and PMCB stock pages for the full models.
Not investment advice.